9.36
price up icon5.88%   0.52
after-market Handel nachbörslich: 9.21 -0.15 -1.60%
loading
Schlusskurs vom Vortag:
$8.84
Offen:
$8.85
24-Stunden-Volumen:
684.95K
Relative Volume:
0.35
Marktkapitalisierung:
$574.45M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-130.41M
KGV:
-3.642
EPS:
-2.57
Netto-Cashflow:
$-67.76M
1W Leistung:
-0.11%
1M Leistung:
+83.89%
6M Leistung:
+65.66%
1J Leistung:
+161.45%
1-Tages-Spanne:
Value
$8.42
$9.37
1-Wochen-Bereich:
Value
$8.31
$9.68
52-Wochen-Spanne:
Value
$2.9106
$12.40

Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile

Name
Firmenname
Monte Rosa Therapeutics Inc
Name
Telefon
617-949-2643
Name
Adresse
321 HARRISON AVENUE, BOSTON
Name
Mitarbeiter
103
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
GLUE's Discussions on Twitter

Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2023-01-03 Hochstufung Wells Fargo Equal Weight → Overweight
2022-10-13 Eingeleitet UBS Buy
2022-08-15 Eingeleitet Jefferies Buy
2022-04-28 Eingeleitet Credit Suisse Neutral
2022-02-10 Eingeleitet Wells Fargo Equal Weight
2021-10-14 Eingeleitet SVB Leerink Mkt Perform
Alle ansehen

Monte Rosa Therapeutics Inc Aktie (GLUE) Neueste Nachrichten

pulisher
Oct 31, 2024

Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade - MSN

Oct 31, 2024
pulisher
Oct 31, 2024

Equities Analysts Issue Forecasts for GLUE FY2024 Earnings - Defense World

Oct 31, 2024
pulisher
Oct 30, 2024

Wedbush Research Analysts Lift Earnings Estimates for GLUE - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics price target raised to $20 from $16 at Piper Sandler - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa, Novartis Partner To Advance Molecular Glue Degraders - Contract Pharma

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis - Yahoo Finance

Oct 29, 2024
pulisher
Oct 29, 2024

This Biotech Stock Has Doubled Its Value Today—Here's Why - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday - MSN

Oct 29, 2024
pulisher
Oct 29, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 By Investing.com - Investing.com Canada

Oct 29, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Soars on Novartis Deal: A Molecular Glue Revolution - BP Journal

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis adds another degrader, this time from Monte Rosa - BioCentury

Oct 28, 2024
pulisher
Oct 28, 2024

This Biotech Almost Doubled On A Massive Deal With Novartis - Investor's Business Daily

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics (NASDAQ:GLUE) Reaches New 52-Week HighTime to Buy? - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa, Novartis have one in VAV1, sign $2.1B pact - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Boston Biotech Announces Novartis Collaboration - Streetwise Reports

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Target of Unusually High Options Trading (NASDAQ:GLUE) - MarketBeat

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics More Than Doubles on Novartis Agreement - MarketWatch

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis - MSN

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis Signs Global License Agreement with Monte Rosa Therapeutics Worth up to $2.1 Billion to Advance MGD-based Therapeutics - BioPharm International

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa's stock doubles on multibillion dollar Novartis deal - The Business Journals

Oct 28, 2024
pulisher
Oct 28, 2024

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal - Barchart

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics stock hits 52-week high at $8.87 - Investing.com India

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa scores $2.1B Novartis deal for molecular glue degraders - BioWorld Online

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa soars as it inks global license deal with Novartis - The Pharma Letter

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa joins with Novartis in ‘molecular glue’ drug deal - BioPharma Dive

Oct 28, 2024
pulisher
Oct 28, 2024

“Top Biotech Opportunities: RVNC, HCTI, GLUE, PRSO, CRDL, Showing Promising Developments” - The Globe and Mail

Oct 28, 2024
pulisher
Oct 28, 2024

Novartis to pay Monte Rosa $150 million upfront to develop a new class of drugs - Reuters

Oct 28, 2024
pulisher
Oct 28, 2024

Why Is Monte Rosa Therapeutics Stock Surging On Monday? - Yahoo Finance

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Shares Soar on Novartis Team-Up - Marketscreener.com

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa jumps on $150M license deal with Novartis (NASDAQ:GLUE) - Seeking Alpha

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa inks $150 million Novartis deal for MRT-6160 By Investing.com - Investing.com Canada

Oct 28, 2024
pulisher
Oct 28, 2024

GLUEMonte Rosa Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Enters Global License Agreement with Novartis - TipRanks

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa inks $150 million Novartis deal for MRT-6160 - Investing.com

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Announces Global License Agreement - GlobeNewswire

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Announces Global License Pact With Novartis To Advance T And B Cell-Modulating Vav1-Directed Molecular Glue Degraders - XM

Oct 28, 2024
pulisher
Oct 28, 2024

Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - StockTitan

Oct 28, 2024
pulisher
Oct 23, 2024

Monte Rosa reports progress on cancer-targeting molecule By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 23, 2024

Monte Rosa reports progress on cancer-targeting molecule - Investing.com

Oct 23, 2024
pulisher
Oct 23, 2024

Monte Rosa Therapeutics Presents Preclinical Data at the - GlobeNewswire

Oct 23, 2024
pulisher
Oct 18, 2024

Objective long/short (GLUE) Report - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 16, 2024

Science Spotlight: Better genomic predictors for Black AML patients - BioCentury

Oct 16, 2024
pulisher
Oct 14, 2024

Dimensional Fund Advisors LP Has $575,000 Position in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Oct 14, 2024
pulisher
Oct 09, 2024

Ratio Analysis: Unpacking Monte Rosa Therapeutics Inc (GLUE)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

GLUE’s latest rating updates from top analysts. - Knox Daily

Oct 09, 2024
pulisher
Oct 07, 2024

Renaissance Technologies LLC Has $953,000 Stock Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - MarketBeat

Oct 07, 2024
pulisher
Oct 05, 2024

American Century Companies Inc. Boosts Holdings in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) - Defense World

Oct 05, 2024
pulisher
Sep 26, 2024

Learn to Evaluate (GLUE) using the Charts - Stock Traders Daily

Sep 26, 2024
pulisher
Sep 25, 2024

Versant Venture sells $7.4m in Monte Rosa Therapeutics stock - Investing.com India

Sep 25, 2024

Finanzdaten der Monte Rosa Therapeutics Inc-Aktie (GLUE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Kapitalisierung:     |  Volumen (24h):